Bio-Rad Laboratories (BIO) Receivables (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Receivables data on file, last reported at $439.5 million in Q1 2026.

• On a quarterly basis, Receivables changed 0.25% year-over-year to $439.5 million in Q1 2026; TTM through Mar 2026 was $439.5 million, a 0.25% change from a year earlier, with the FY2025 full-year figure at $472.5 million, up 1.48% from the prior year.
• Receivables for Q1 2026 stood at $439.5 million, down from $472.5 million in the prior quarter.
• Over the last five years, Receivables for BIO reached as high as $513.1 million in Q1 2023 and fell as low as $438.4 million in Q1 2025.
• Historically, Receivables has averaged $471.4 million across 5 years, with a median of $470.7 million in 2022.
• Across the five-year window, Receivables increased 18.91% in 2022 and fell 10.42% in 2024, its largest moves.
• Year by year, Receivables stood at $506.2 million in 2022, then declined by 1.06% to $500.9 million in 2023, then retreated by 7.05% to $465.6 million in 2024, then grew by 1.48% to $472.5 million in 2025, then fell by 6.98% to $439.5 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $439.5 million in Q1 2026, $472.5 million in Q4 2025, and $474.2 million in Q3 2025.